Clinical Trial Detail

NCT ID NCT01920061
Title A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Pfizer
Indications

ovarian cancer

lung non-small cell carcinoma

triple-receptor negative breast cancer

gastroesophageal junction adenocarcinoma

head and neck squamous cell carcinoma

transitional cell carcinoma

breast cancer

prostate cancer

Therapies

Dacomitinib + Gedatolisib

Cisplatin + Gedatolisib

Docetaxel + Gedatolisib

Age Groups: adult senior

Additional content available in CKB BOOST